You are here: Industry Insights > Anti-PD-1

News List

Dr Reddy’s presents preclinical data for E7777 (denileukin diftitox) and an immune checkpoint inhibitor at SITC 2020 expresspharma
November 10, 2020
The data reveals significant improvement in tumour growth inhibition and overall survival through a combination of E7777 (Denileukin Diftitox) and an immune checkpoint inhibitor.
Electronic Nose Analysis May Predict Response to Anti-PD-1 Therapy in NSCLC drugs
September 19, 2019
For patients with non-small cell lung cancer (NSCLC), responders and nonresponders can be differentiated by a metal oxide semiconductor electronic nose (eNose) analysis of exhaled breath before starting ...
Different Clinical Layouts of Chinese-produced Products for Marching into the Anti-PD-1 Monoclonal Antibody Market PharmaSources/Xiaoyaowan
July 04, 2019
The marketing of camrelizumab means the beginning of the next stage of competition for layouts centering on multiple new indications.
A Review of Progress of Immunotherapy Drugs for Hodgkin’s Lymphoma PharmaSources/Yefenghong
July 03, 2019
The news widespread in the industry that Hengrui has received the pharmaceutical product registration approval for its anti-PD-1 camrelizumab has been confirmed recently. It took 24 days from the beginning of review to the receipt of approval on May 29.
Anti-PD-1/PD-L1 Monoclonal Antibodies: Not Easy to Let Go (2) Mr. Nanguo
May 02, 2018
Whether products have unique advantages is a criterion for considering whether they can be further advanced.
Anti-PD-1/PD-L1 Monoclonal Antibodies: Not Easy to Let Go (1) Mr. Nanguo
May 02, 2018
Anti-PD-1/PD-L1 monoclonal antibodies, the trailbreaker of tumor immunotherapies, have been chased after by the market since marketing, and become the battleground of international pharmaceutical giants.